Comparative Efficacy Study Combination of Oral Methotrexate and Prednisolone versus Oral Methotrexate in Patients with Lichen Planopilaris

Table 6

Comparison of sign and symptoms between combined and methotrexate therapy at the baseline and within the follow-up.

	Baseline			Two months after intervention			Four months after intervention			Six months after intervention
	MTX	COM		MTX	COM		MTX	COM		MTX	COM
Pain, n (%)
No	10 (71.43)	8 (57.14)	0.745	11 (91.67)	11 (91.67)	0.999	11 (91.67)	12 (100)	—	12 (100.0)	12 (100.0)	—
Mild	3 (21.43)	4 (28.57)		0 (0)	1 (8.33)		1 (8.33)	0 (0)		0 (0)	0 (0)
Moderate	1 (7.14)	2 (14.29)		1 (8.33)	0 (0)		0 (0)	0 (0)		0 (0)	0 (0)
Severe	0 (0)	0 (0)		0(0)	0 (0)		0 (0)	0 (0)		0 (0)	0 (0)
Pruritus, n (%)
No	2 (14.29)	2 (14.29)	0.877	4 (33.33)	6 (50)	0.663	5 (41.67)	10 (83.33)	0.115	6 (50)	10 (83.33)	0.244
Mild	2 (14.29)	4 (28.57)		5 (41.67)	5 (41.67)		5 (41.67)	2 (16.67)		4 (33.33)	2 (16.67)
Moderate	4 (28.57)	4 (28.57)		3 (25)	1 (8.33)		1 (8.33)	0 (0)		2 (16.67)	0 (0)
Severe	6 (42.86)	4 (28.57)		0 (0)	0 (0)		1 (8.33)	0 (0)		0 (0)	0 (0)
Soreness, n (%)
No	8 (57.14)	8 (57.4)	0.745	10 (83.33)	9 (75.00)	0.50	9 (75.00)	12 (100.00)	0.217	11 (91.67)	12 (100)	0.50
Mild	5 (35.71)	3 (21.43)		2 (16.67)	3 (25.0)		2 (16.67)	0 (0)		1 (8.33)	0 (0)
Moderate	1 (7.14)	2 (14.29)		0 (0)	0 (0)		1 (8.33)	0 (0)		0 (0)	0 (0)
Severe	0 (0)	1 (7.14)		0 (0)	0 (0)		0 (0)	0 (0)		0 (0)	0 (0)
Erythema, n (%)
No	5 (35.71)	3 (21.43)	0.580	6 (50)	4 (33.33)	0.236	6 (50)	7 (58.33)	0.999	10 (83.33)	10 (83.33)	0.999
Mild	4 (28.57)	2 (14.29)		5 (41.67)	3 (25)		5 (41.67)	4 (33.33)		0 (0)	1 (8.33)
Moderate	4 (28.57)	6 (42.86)		1 (8.33)	5 (41.67)		1 (8.33)	1 (8.33)		2 (16.67)	1 (8.33)
Severe	1 (7.14)	3 (21.43)		0 (0)	0 (0)		0 (0)	0 (0)		0 (0)	0 (0)
Perifollicular erythema, n (%)
No	1 (7.14)	0 (0)	0.707	1 (8.33)	2 (16.67)	0.043	7 (58.33)	7 (58.33)	0.418	5 (41.67)	7 (58.33)	0.684
Mild	5 (35.71)	6 (42.86)		10 (83.33)	4 (33.33)		5 (41.67)	3 (25)		6 (50)	5 (41.67)
Moderate	5 (35.71)	3 (21.43)		0 (0)	4 (33.33)		0 (0)	2 (16.67)		1 (8.33)	0 (0)
Severe	3 (21.43)	5 (35.71)		1 (8.33)	2 (16.67)		0 (0)	0 (0)		0 (0)	0 (0)
Perifollicular scaling, n (%)
No	2 (14.29)	4 (28.57)	0.766	2 (16.67)	3 (25)	0.067	5 (41.67)	3 (25)	0.528	2 (16.67)	3 (25)	0.564
Mild	7 (50)	4 (28.57)		7 (58.33)	2 (16.67)		4 (33.33)	2 (16.67)		5 (41.67)	2 (16.67)
Moderate	3 (21.43)	4 (28.57)		1 (8.33)	6 (50)		2 (16.67)	4 (33.33)		4 (33.33)	4 (33.33)
Severe	2 (14.29)	2 (14.29)		2 (16.67)	1 (8.33)		1 (8.33)	3 (25)		1 (8.33)	3 (25)
Pull test, n (%)
No	8 (57.14)	9 (64.29)	0.50	12 (100)	12 (100)	—	12 (100)	12 (100)	—	12 (100)	12 (100)	—
Presence	6 (42.86)	5 (35.71)		0 (0)	0 (0)		0 (0)	0 (0)		0 (0)	0 (0)
Spreading, n (%)
No	0 (0)	8 (57.14)	<0.001	8 (66.67)	9 (75)	0.202	9 (75)	12 (100)	0.217	10 (83.33)	12 (100)	0.478
Intermediate	1 (7.14)	3 (21.43)		1 (8.33)	3 (25)		1 (8.33)	0 (0)		2 (16.67)	0 (0)
Presence	13 (92.86)	3 (21.43)		3 (25)	0 (0)		2 (16.67)	0 (0)		0 (0)	0 (0)
Follicular keratosis, n (%)
No	0 (0)	0 (0)	0.162	0 (0)	0 (0)	0.648	0 (0)	0 (0)	0.158	1 (8.33)	1 (8.33)	0.784
Mild	4 (28.57)	7 (50)		8 (66.67)	6 (50)		8 (66.67)	11 (91.67)		8 (66.67)	10 (83.33)
Moderate	7 (50)	2 (14.29)		3 (25)	3 (25)		4 (33.33)	1 (8.33)		3 (25)	1 (8.33)
Severe	3 (21.43)	5 (35.71)		1 (8.33)	3 (25)		0 (0)	0 (0)		0 (0)	0 (0)

MTX: methotrexate; COM: combined therapy.